Rare Tumors · 2013 · 10 citations · 12 references
MedicineOncologyPharmacotherapyMetastasisNeoplasiaTumor ProgressionMalignant NeoplasmsMalignant TumorsMetastatic Disease ManagementMetastatic Disease TreatmentMtor Inhibitor TherapyTargeted TherapyMalignant ProgressionMtor InhibitionMtor SignalingTranscatheter Arterial EmbolizationTranscatheter EmbolizationTreatment StrategiesTumor EmbolizationYoung Women
Epithelioid angiomyolipomas (EAMLs) are rare mesenchymal tumors whose malignant variant is extremely uncommon and highly aggressive. Treatment strategies include chemo radiation, transcatheter arterial embolization and surgical resection, which has remained the mainstay treatment. Targeted therapies including mammalian target of rapamycin (mTOR) inhibitors such as Temsirolimus may offer some hope for progressive malignant EAMLs that are not amenable to other treatment modalities. We report a fatal case in a young female who presented with rapidly progressive metastatic EAML that did not respond to mTOR therapy. The literature has shown reduction in tumor burden with the use of mTOR inhibitors, but unfortunately due to the rarity of malignant EAML, a meaningful approach to treatment remains challenging.
12
Cristina Magi‐Galluzzi, Brian R. Lane, Linda Sercia et al. · The American Journal of Surgical Pathology · 2009 · 252 citations
Clinical presentation of epithelioid angiomyolipoma
Hang Kyu Park, Shaozeng Zhang, Michael K. Wong et al. · International Journal of Urology · 2006 · 69 citations · Full text